Brigham & Women’s Hospital
Department of Medicine
Division of Pharmacoepidemiology & Pharmacoeconomics
1620 Tremont Street, Suite 3030,
Boston, MA 02120
Phone: 617-278-0930 | Fax: 617-232-8602
Assistant: Ms. Paula Cole, firstname.lastname@example.org
Sebastian Schneeweiss is Vice Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine of the Brigham and Women’s Hospital. He is a Professor of Medicine at Harvard Medical School and Professor in Epidemiology at the Harvard School of Public Health.
Dr. Schneeweiss works on the comparative effectiveness and safety of biopharmaceuticals and developing methods to reach causal conclusions from analyzing complex healthcare databases. He focuses on newly marketed medications and how real-world evidence can be generated expeditiously at highest quality without compromising the accuracy of findings. He applies data-adaptive algorithms to large healthcare databases to improve confounding control supporting causal inference. Automatization of these analytics in order to generate new evidence in rapid cycles is part of his focus. Disease areas of interest include cardiovascular, antithrombotic therapy, rheumatology, mental health, and others. He teaches courses in principled database analytics in pharmacoepidemiology at Harvard and in Europe.
He is Principal Investigator of the Harvard-Brigham Drug Safety Research Center funded by FDA/CDER. His research is funded by multiple NIH grants. Dr. Schneeweiss is Past President of the International Society for Pharmacoepidemiology and is Fellow of the American College of Epidemiology, the American College of Clinical Pharmacology, and the International Society for Pharmacoepidemiology. He is voting consultant to the FDA Drug Safety and Risk Management Advisory Committee and past inaugural member of the Methods Committee of the Patient Centered Outcomes Research Institute.
He received his medical training at the University of Munich Medical School and his masters and doctoral degrees in Pharmacoepidemiology from Harvard.
Current Courses Taught
EPI286 Database Analytics in Pharmacoepidemiology (Fall 2017) – This course is intended primarily for graduate students considering a career in the pharmaceutical/biotech industry, pharmaceutical benefits management, or in national regulatory bodies. Students will learn to design, implement and interpret pharmacoepidemiologic studies using longitudinal healthcare databases. (Dr. Schneeweiss, Dr. Gagne)
EPI253 Effectiveness Research with Longitudinal Healthcare Databases (Summer 2017) – The target audience consists of researchers working in academia, medical product industry, health plans, government institutions, regulatory agencies, who have access to large longitudinal healthcare databases. They may use healthcare databases to evaluate the effectiveness of medical interventions and care patterns, to understand the comparative effectiveness and safety of medical products, to test the impact of coverage changes, or to monitor the outcome of risk-sharing arrangements. (Dr. Schneeweiss, Dr. Fischer, Dr. Hernandez-Diaz)
Effectiveness Research with Longitudinal Healthcare Databases (Summer 2017) – As part of the Summer School on Modern Methods In Biostatistics and Epidemiology, Treviso, Italy, Dr. Schneeweiss teaches the analysis of complex longitudinal healthcare databases. Participants from academia, medical product industry, health plans, government institutions, regulatory agencies will design, implement and interpret their own database analysis using the Aetion platform to assess the value of a medical intervention. (Dr. Schneeweiss, Dr. Patorno)
Selected Publications | Current PubMed Search Results
- Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017;376:2300-2.
- Bohn J, Eddings W, Schneeweiss S. Privacy-preserving propensity score analysis when patient covariate information is stored in separate locations. Am J Epidemiol 2017;185:501-10.
- Schneeweiss S, Eddings W, Glynn RJ, Patorno E, Rassen RA, Franklin JM. Variable selection for confounding adjustment in high-dimensional covariate spaces when analysing healthcare databases. Epidemiology 2017;28:237-48.
- Schneeweiss S, Eichler HG, et al. Real world data in adaptive biomedical innovation: A framework for generating evidence fit for decision-making. Clin Pharm Ther 2016;100:633-46.
- Kumamaru H, Gagne JJ, Glynn RJ, Setoguchi S, Schneeweiss S. Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. J Clin Epidemiol 2016;76:200-8.
- Schneeweiss S. Improving therapeutic effectiveness and safety through big healthcare data. Clin Pharm Ther 2016; 99:262-5.
- Schneeweiss S, Shrank W, Ruhl M, Maclure M. Decision-making aligned with rapid-cycle evaluation in healthcare. Int J Tech Ass Healthcare 2015;31:214-22.
- Franklin JM, Eddings W, Glynn RJ, Schneeweiss S. Regularized regression versus high-dimensional propensity score for confounding adjustment in secondary database analyses. Am J Epidemiol 2015;182:651-9.
- Schneeweiss S. Learning from big health care data. N Engl J Med 2014; 370:2161-3.
- Jackson JW, VanderWeele TJ, Viswanathan A, Blacker D, Schneeweiss S. The Explanatory Role of Stroke as a Mediator of the Mortality Risk Difference Between Older Adults Who Initiate First- Versus Second-Generation Antipsychotic Drug. Am J Epidemiol. 2014;180:847-52.
- Patorno E, Glynn RJ, Hernandez-Diaz S, Schneeweiss S. Covariate selection and implementation of propensity-score-based confounding adjustment in studies with many covariates and few outcomes: Anticonvulsants and cardiovascular risk. Epidemiology 2014 in press.
- Patrick A, Meyers J, Weinstein M, Glynn RJ, Schneeweiss S. Sequential value of information assessment in prospective drug safety monitoring using claims databases: The comparative safety of prasugrel versus clopidogrel. Med Decision Making 2013;33:949-60.
- Walker AM, Patrick AR, Lauer MS, Hornbrook MC, Marin MG, Platt R, Roger VL, Stang P, Schneeweiss S. A Tool for Assessing the Feasibility of Comparative Effectiveness Research. Comp Effect Res 2013;3:11-20.
- Rassen JA, Shelat AA, Myers J, Glynn RJ, Schneeweiss S. Matching by propensity score in cohort studies with three treatment groups. Epidemiology 2013;24:401-9.
- Schneeweiss S, Suissa S. Advanced approaches to controlling confounding in pharmacoepidemiologic studies, pp. 324-36. In: Strom BL, Kimmel SE, Hennessey S: Textbook of Pharmacoepidemiology, 2nd edition, John Wiley&Sons, Chichester, 2013.
- Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, Solomon DH, Kim SJ, Rothman KJ, Liu J, Avorn J. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Medical Research Methodology. 2012;12:180,1-15.
- Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5:480-6
- Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 2:138-47.
- Rassen JA, Schneeweiss S. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:41-9.
- Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012;23:238-46.
- Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JR. Assessing the comparative effectiveness of newly marketed medications. Clin Pharm Ther 2011;90:777-90.
- Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.JAMA 2011;305:2525-31.
- Rassen JA, Solomon DH, Glynn RJ, Schneeweiss S. Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic “matrix design”. Pharmacoepidemiol Drug Saf 2011;20:675-83.
- Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples.Am J Epidemiology 2011;173:1404-13.
- Huybrechts K, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of Death and Hospitalization for Major Medical Events after Initiation of Psychtropic Medications in Older Adults Admitted to Nursing Homes.Can Med Assoc J 2011;183:411-9.
- Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, Schneeweiss S. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death.JAMA 2010;303:1401-9.
- Solomon DH, Rassen JA, Glynn RJ, Levin R, Lee J,Schneeweiss S, The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 2010;170:1979-86
- Schneeweiss S, A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Safety 2010;19:858-68.
- Schneeweiss S, Rassen JR, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512–22.
- Schneeweiss S, Patrick AR, Pedan A, Varasteh L, Levin R, Liu N, Shrank WH. The effect of Medicare Part D drug coverage on drug use and out-of-pocket spending in seniors without prior drug benefits. Health Affairs 2009;28:w305-16.
- Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol & Ther 2009;30:253–64.
- Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during CABG surgery and risk of death. N Engl J Med 2008; 358:840-2.
- Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharm Ther 2007;82:143-56.
- Schneeweiss S, Patrick AR, Maclure M, Dormuth C, Glynn RJ. Adherence to statin therapy under drug cost-sharing in patients with and without acute MI: A population-based natural experiment. Circulation 2007;115:2128-35.
- Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiiflamatory drugs.Arthritis Rheum 2006;54:3390-8.
- Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Safety 2006;15:291-303.
- Wang PS, Schneeweiss S, Avorn J, Fischer MF, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41.
- Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology 2005;16:17-24.
- Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 2004;351:2187-2194.
- Schneeweiss S, Maclure M, Carleton B, Glynn RJ, Avorn J. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. BMJ 2004;328:560-7.
- Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting enzyme inhibitors. N Engl J Med 2002;346:822-829.
- Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-864.
- Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Safety 1997;6(S3):51-9.